Medical Oncologist
Targeted therapy
Tumour-Agnostic Drugs: — When the Mutation Matters More Than the Organ
A tumour-agnostic drug is approved based on a specific genetic change inside your tumour, not the organ where the cancer started. If your pathology report shows a qualifying mutation, you may be eligible for treatment — regardless of whether the cancer is in the colon, lung, thyroid, or anywhere else.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Mutation decides eligibility — The test looks for a specific change in your tumour's DNA. The organ the cancer is in does not determine whether you qualify.
- Approved for any solid tumour type — If the qualifying mutation is present, regulatory agencies approve these drugs regardless of where the cancer started.
- Your existing biopsy is usually enough — A new biopsy is only needed if the original sample is too small or too degraded for molecular testing.
- Most patients will not qualify — Qualifying mutations are found in a minority of cancers. Not qualifying means a different treatment fits your tumour better — not that options are limited.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Tumour-agnostic drugs are approved based on a specific mutation in your tumour's DNA, not the organ where your cancer started. If your tumour carries a qualifying change — such as MSI-H, an NTRK fusion, a RET fusion, or a BRAF V600E mutation — you may be eligible regardless of your cancer type.
Which mutations make you eligible for a tumour-agnostic drug?
The mutations with established tumour-agnostic approvals from regulatory agencies include MSI-H and dMMR, NTRK gene fusions, RET gene fusions, BRAF V600E mutations, and high tumour mutational burden (TMB-H). NCCN and ASCO guidelines now recommend testing for each of these as part of comprehensive molecular profiling.
MSI-H (microsatellite instability-high) and dMMR (mismatch repair deficiency) are tested using immunohistochemistry or PCR. They occur across many cancer types — most commonly in colorectal, endometrial, and gastric cancers — and checkpoint inhibitor therapy has received tumour-agnostic regulatory approval for patients whose tumours carry these markers.
NTRK gene fusions are rare but can occur in many cancer types, including thyroid, salivary gland, lung, and colorectal cancers. Larotrectinib and entrectinib have received tumour-agnostic approval for solid tumours with an NTRK fusion, regardless of origin. RET fusions and BRAF V600E mutations have similarly received tumour-agnostic approvals, each with a corresponding targeted drug.
How do you find out if your tumour has a qualifying mutation?
Start with your existing biopsy tissue
The laboratory uses tissue already taken during your diagnostic biopsy in most cases. A new biopsy is only needed if the original sample is too small, too degraded, or if your disease has changed significantly since the original procedure.
Your oncologist orders molecular profiling
Next-generation sequencing (NGS) reads your tumour's DNA to look for fusions, mutations and other changes all at once. For MSI-H and dMMR, immunohistochemistry (IHC) is the standard first test and is available at most large pathology laboratories across India.
Results are returned from the laboratory
IHC results come back sooner than NGS panels. NGS takes longer, and samples sent to specialist centres may need additional time. Ask your oncologist to give you a specific date to expect results so you are not waiting without a timeline.
Your oncologist matches the finding to regulatory approvals
Not every detected mutation has a tumour-agnostic approval. Your oncologist checks whether the specific change found corresponds to an approved indication and whether your stage and general fitness make you a suitable candidate.
A treatment recommendation is made
If a qualifying mutation is confirmed and you are otherwise suitable, a tumour-agnostic drug may be recommended. If not, your oncologist will explain which approved treatments apply to your specific cancer type instead.
What does treatment look like if you have a qualifying mutation?
Most tumour-agnostic drugs are given intravenously as day care. Some — including larotrectinib — are oral tablets taken daily. Your oncologist will explain the specific drug, how often it is given, and what monitoring is required.
Treatment continues as long as it is working and you are tolerating it. Response is assessed with regular imaging at intervals your oncologist will define. Side effects differ significantly depending on which drug is used — checkpoint inhibitors carry immune-related risks, while NTRK or RET inhibitors have their own distinct profile. Your team will explain what to expect for the specific treatment recommended.
At CION, immunotherapy is given as day care, and targeted oral drugs are managed with regular clinic follow-up and monitoring.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
How common are qualifying mutations — and what if you do not have one?
Qualifying mutations are found in a minority of patients. MSI-H is more commonly found in colorectal, endometrial, and gastric cancers than in most other tumour types. NTRK fusions are rare across the board. Being tested and not qualifying is not a setback — it means a different treatment is the better match for your particular tumour.
Not qualifying does not mean options are limited. It means the evidence points to a different approach — chemotherapy, another targeted therapy, radiation, or a combination. Your oncologist will outline what that looks like for your diagnosis.
Eligibility can also change. If your cancer recurs or progresses, re-testing may be appropriate — new tumour-agnostic approvals continue to emerge. Ask your oncologist whether repeat molecular profiling is worth considering at that stage.
Questions patients ask about tumour-agnostic testing
Can I ask for this testing myself, without waiting for my oncologist to order it?
You can raise it as a question, and it is a reasonable one. But the right panel to order depends on your specific cancer type, and a broad NGS test arranged without that context can return results that are difficult to interpret without specialist guidance. The more practical step is to ask your oncologist directly whether comprehensive molecular profiling has been done — or whether it should be. Ask to see the results in writing once they are available.
Do I need a new biopsy to get molecular testing done?
Usually not. Molecular testing is done on the fixed tissue block from your original biopsy, which is stored by the pathology laboratory. A new biopsy is only needed when that block is insufficient, degraded, or represents an early stage of disease that may no longer reflect the current tumour. If you had a biopsy recently, ask your oncologist whether the existing block is adequate before agreeing to any repeat procedure.
What is next-generation sequencing and why does it cost more than standard tests?
Next-generation sequencing reads large sections of your tumour's DNA in one run and can detect multiple types of changes — fusions, mutations, insertions and deletions — simultaneously. Standard tests such as IHC look for one marker at a time. NGS requires specialist equipment and bioinformatic analysis, which is reflected in the cost. The advantage is that it can look for several qualifying mutations in a single test rather than ordering each test separately. Discuss the cost and which panel is appropriate with your oncologist before ordering.
Are tumour-agnostic drugs approved and available in India?
Regulatory approvals for tumour-agnostic drugs in India are handled by CDSCO and are updated over time. Some drugs approved by the FDA for tumour-agnostic indications are also available in India; others may be accessible through import or other routes. Your oncologist is the right person to confirm what is currently approved by CDSCO, what the practical access pathway looks like for your mutation, and what costs are likely — rather than relying on information from a fixed source such as this page, which may not reflect the latest regulatory position.
Will Ayushman Bharat or health insurance cover the testing and treatment?
Coverage depends on your specific scheme or policy and changes over time. Neither Ayushman Bharat nor private insurer policies are uniform across all tumour-agnostic drugs or NGS panels. Ask the hospital's medical social worker or billing team to check your entitlement before ordering tests or starting treatment. Some policies require prior authorisation, and starting without it can result in claims being declined. Getting clarity in writing before you begin protects you.
Does CION offer tumour-agnostic treatment?
Yes. Tumour-agnostic immunotherapy is given as day care at CION centres for patients who qualify. Targeted oral therapies are managed with regular clinic follow-up and monitoring. Molecular testing is coordinated with partner laboratories, and your oncologist at CION will advise which tests are appropriate for your diagnosis and arrange them. CION does not provide CAR-T or cell therapy; if that is being discussed for your situation, you would be referred to a centre that offers it.
Did you know?
MSI-H and dMMR testing is now recommended by NCCN for all patients with colorectal cancer at the time of diagnosis — making it one of the most routinely ordered tumour-agnostic tests in oncology.
The same test that identifies hereditary Lynch syndrome also identifies patients who may be eligible for checkpoint inhibitor therapy, meaning a single result can answer two clinically important questions at once.
Source: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Which cancers are most likely to have a qualifying tumour-agnostic mutation?
MSI-H and dMMR are most commonly found in colorectal, endometrial, and gastric cancers, though they can occur in any tumour type. NTRK fusions are rare overall but are relatively more common in certain rare cancers such as secretory breast cancer and papillary thyroid cancer. RET fusions are seen in lung and thyroid cancers among others. Because prevalence varies widely, the only answer that matters for your situation is your own molecular profiling result — a population frequency does not tell you whether the mutation is present in your specific tumour.
Can a tumour-agnostic drug be used alongside chemotherapy?
In some settings, yes. For certain qualifying indications, checkpoint inhibitor therapy is approved both as a single agent and in combination with chemotherapy. Whether a combination applies to you depends on your cancer type, stage, and prior treatment history — not just the biomarker result. Your oncologist will explain which regimen is recommended for your specific situation and what combining treatments adds compared to either one alone.
How long does molecular testing take in India, and where is it done?
IHC for MSI-H and dMMR is available at most large pathology laboratories and typically returns results faster than NGS panels. NGS panels take longer and may require the sample to be sent to a specialist laboratory if your treating hospital does not run the panel in-house. Ask your oncologist when the sample was dispatched and when the result is expected — having a specific date prevents unnecessary uncertainty. Some laboratories offer faster turnaround for an additional charge.
If the mutation is found, does that mean the drug will definitely work?
A qualifying mutation makes you eligible for the treatment — it does not guarantee a response. In the patients who do respond, the benefit can be substantial and sustained, but a proportion of eligible patients do not respond, and it is not currently possible to predict in advance who will be in which group. Your oncologist will explain what the evidence shows for your specific mutation and cancer type, and what will be assessed to determine whether the treatment is working for you.
Can the mutation change or disappear over time?
Tumours can change their molecular characteristics as they grow or as treatment applies selective pressure. A mutation present at diagnosis may not be present in the same form at recurrence. Occasionally a mutation not detected early appears later. This is one reason why re-testing at progression is sometimes recommended — particularly if it has been some years since the original profiling, or if new tumour-agnostic approvals have emerged since then. Ask your oncologist whether repeat molecular testing is appropriate if your situation changes.
What should I ask my oncologist about tumour-agnostic testing?
Ask three things: whether comprehensive molecular profiling has been done on your tumour tissue and what it showed; whether any mutation found corresponds to a tumour-agnostic drug approved for your situation; and if not, whether re-testing should be considered if your disease changes. Ask for the results in writing — a report naming the specific mutations tested, their status, and the laboratory that ran the panel. That report is useful if you seek a second opinion, and it may become relevant again if new approvals emerge for your cancer type.